• Something wrong with this record ?

Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria

C. Eckmann, W. Lawson, D. Nathwani, CT. Solem, JM. Stephens, C. Macahilig, D. Simoneau, P. Hajek, C. Charbonneau, R. Chambers, JZ. Li, S. Haider,

. 2014 ; 44 (1) : 56-64.

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15014223

This retrospective observational medical chart review aimed to describe country-specific variations across Europe in real-world meticillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infection (cSSTI) treatment patterns, antibiotic stewardship activity, and potential opportunities for early switch (ES) from intravenous (i.v.) to oral formulations and early discharge (ED) from hospital using standardised data collection and criteria and economic implications of these opportunities. Patients were randomly sampled from 12 countries (Austria, Czech Republic, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Slovakia, Spain and the UK), aged ≥18 years, with documented MRSA cSSTI, hospitalised between 1 July 2010 and 30 June 2011, discharged alive by 31 July 2011. Of 1502 patients, 1468 received MRSA-targeted therapy. Intravenous-to-oral switch rates ranged from 2.0% to 20.2%, i.v. length of therapy from 10.1 to 18.6 days and hospital length of stay (LoS) from 15.2 to 25.0 days across Europe. Of 341 sites, 82.9% had antibiotic steering committees, 23.7% had i.v.-to-oral switch antibiotic protocols and 12.9% had ED protocols for MRSA cSSTI. ES and ED eligibility ranged from 12.0% (Slovakia) to 56.3% (Greece) and from 10% (Slovakia) to 48.2% (Portugal), respectively. Potential cost savings per ED-eligible patient ranged from €414 (Slovakia) to €2703 (France). MRSA cSSTI treatment patterns varied widely across countries, but further reductions in i.v. therapy, hospital LoS and associated costs could be realised. These data provide insight into clinical practice patterns across diverse European healthcare systems and identify potential opportunities for local clinicians and policy-makers to improve clinical care and cost-effectiveness of this therapeutic area.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014223
003      
CZ-PrNML
005      
20150427111615.0
007      
ta
008      
150420s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijantimicag.2014.04.007 $2 doi
035    __
$a (PubMed)24928311
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Eckmann, Christian $u Klinikum Peine and Medical University Hannover, Peine, Germany.
245    10
$a Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria / $c C. Eckmann, W. Lawson, D. Nathwani, CT. Solem, JM. Stephens, C. Macahilig, D. Simoneau, P. Hajek, C. Charbonneau, R. Chambers, JZ. Li, S. Haider,
520    9_
$a This retrospective observational medical chart review aimed to describe country-specific variations across Europe in real-world meticillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infection (cSSTI) treatment patterns, antibiotic stewardship activity, and potential opportunities for early switch (ES) from intravenous (i.v.) to oral formulations and early discharge (ED) from hospital using standardised data collection and criteria and economic implications of these opportunities. Patients were randomly sampled from 12 countries (Austria, Czech Republic, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Slovakia, Spain and the UK), aged ≥18 years, with documented MRSA cSSTI, hospitalised between 1 July 2010 and 30 June 2011, discharged alive by 31 July 2011. Of 1502 patients, 1468 received MRSA-targeted therapy. Intravenous-to-oral switch rates ranged from 2.0% to 20.2%, i.v. length of therapy from 10.1 to 18.6 days and hospital length of stay (LoS) from 15.2 to 25.0 days across Europe. Of 341 sites, 82.9% had antibiotic steering committees, 23.7% had i.v.-to-oral switch antibiotic protocols and 12.9% had ED protocols for MRSA cSSTI. ES and ED eligibility ranged from 12.0% (Slovakia) to 56.3% (Greece) and from 10% (Slovakia) to 48.2% (Portugal), respectively. Potential cost savings per ED-eligible patient ranged from €414 (Slovakia) to €2703 (France). MRSA cSSTI treatment patterns varied widely across countries, but further reductions in i.v. therapy, hospital LoS and associated costs could be realised. These data provide insight into clinical practice patterns across diverse European healthcare systems and identify potential opportunities for local clinicians and policy-makers to improve clinical care and cost-effectiveness of this therapeutic area.
650    _2
$a acetamidy $x ekonomika $x terapeutické užití $7 D000081
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x ekonomika $x terapeutické užití $7 D000900
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hospitalizace $x ekonomika $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a injekce intravenózní $7 D007275
650    _2
$a délka pobytu $x ekonomika $x statistika a číselné údaje $7 D007902
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methicilin rezistentní Staphylococcus aureus $x účinky léků $x růst a vývoj $7 D055624
650    _2
$a lidé středního věku $7 D008875
650    _2
$a oxazolidinony $x ekonomika $x terapeutické užití $7 D023303
650    _2
$a propuštění pacienta $7 D010351
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a infekce měkkých tkání $x farmakoterapie $x ekonomika $x mikrobiologie $x patologie $7 D018461
650    _2
$a stafylokokové infekce kůže $x farmakoterapie $x ekonomika $x mikrobiologie $x patologie $7 D013207
650    _2
$a vankomycin $x ekonomika $x terapeutické užití $7 D014640
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lawson, Wendy $u Imperial College Healthcare NHS Trust, London, UK.
700    1_
$a Nathwani, Dilip $u Ninewells Hospital & Medical School, Dundee, UK.
700    1_
$a Solem, Caitlyn T $u Pharmerit International, Bethesda, MD, USA.
700    1_
$a Stephens, Jennifer M $u Pharmerit International, Bethesda, MD, USA. Electronic address: jstephens@pharmerit.com.
700    1_
$a Macahilig, Cynthia $u Medical Data Analytics, Parsippany, NJ, USA.
700    1_
$a Simoneau, Damien $u Pfizer IO, Paris, France.
700    1_
$a Hajek, Petr $u Pfizer Inc., Prague, Czech Republic.
700    1_
$a Charbonneau, Claudie $u Pfizer IO, Paris, France.
700    1_
$a Chambers, Richard $u Pfizer Inc., Collegeville, PA, USA.
700    1_
$a Li, Jim Z $u Pfizer Inc., La Jolla, CA, USA.
700    1_
$a Haider, Seema $u Pfizer Inc., Groton, CT, USA.
773    0_
$w MED00005050 $t International journal of antimicrobial agents $x 1872-7913 $g Roč. 44, č. 1 (2014), s. 56-64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24928311 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150427111919 $b ABA008
999    __
$a ok $b bmc $g 1071804 $s 897101
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 44 $c 1 $d 56-64 $i 1872-7913 $m International journal of antimicrobial agents $n Int J Antimicrob Agents $x MED00005050
LZP    __
$a Pubmed-20150420

Find record

Citation metrics

Archiving options